Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
CheckMate 8HW Trial at ASCO 2025: Nivolumab Plus Ipilimumab Sets New ...
CheckMate 77T Trial: Perioperative Nivolumab Plus Chemotherapy in Stage ...
CheckMate 577 Final Results: Adjuvant Nivolumab Sustains Disease-Free ...
CheckMate 73L: A Phase 3 Study Comparing Nivolumab Plus Concurrent ...
Treatment-Switching Adjustment of Overall Survival in CheckMate 227 ...
CheckMate 214 Updates: Nivolumab Plus Ipilimumab Versus Sunitinib in ...
481TiP Checkmate 722: A phase 3 trial of nivolumab with chemotherapy or ...
Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 ...
Summary of CheckMate Trials Involving Nivolumab | Download Table
(PDF) First-line nivolumab + ipilimumab in advanced NSCLC: CheckMate ...
CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients ...
CheckMate 214 Trial Final 9-Year Results at ASCO 2025: Nivolumab Plus ...
Three-year follow-up and patient-reported outcomes from CheckMate 078 ...
CheckMate 227 Part 1: 4-Yr Update - Slideset Download - Clinical ...
Efficacy and safety results from CheckMate 140, a phase 2 study of ...
(PDF) CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline ...
| Comparisons between the CheckMate 227 trial and simulation, overall ...
CheckMate 171: A phase 2 trial of nivolumab in patients with previously ...
Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab versus ...
𝐂𝐡𝐚𝐧𝐝𝐥𝐞𝐫 𝐏𝐚𝐫𝐤 𝐌𝐃 𝐅𝐀𝐂𝐏 on Twitter: "⚡️ Checkmate 274 trial UPDATE at ...
Nivolumab Plus Chemotherapy in Epidermal Growth Factor Receptor–Mutated ...
肺癌丨纳武利尤单抗(O药)系列研究汇总|肺癌|研究|化疗|治疗|-健康界
(A) Study design of Keynote-789 and (B) Checkmate-722. | Download ...
(PDF) CheckMate-722: The Rise and Fall of Nivolumab with Chemotherapy ...
Nivolumab, Pomalidomide, and Elotuzumab Combination Regimens for ...
Table 1 from Nivolumab Plus Chemotherapy in Epidermal Growth Factor ...
Frontiers | Nivolumab adjuvant therapy for esophageal cancer: a review ...
ASCO GU 2025: Nivolumab plus Cabozantinib vs Sunitinib for Previously ...
Nivolumab plus chemotherapy in first-line metastatic non-small-cell ...
clin
ASCO GU 2020: Overall Survival and Independent Review of Response in ...
SI GRÍFOLS NO QUIERE PASAR POR UNA JUNTA " BOCHORNOSA " ... MUCHO ...
Tony Mok教授点评:ORIENT-31和SUNRISE研究是否回答了这些问题?医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate ...
ASCO GU 2024: Nivolumab plus Ipilimumab vs Sunitinib for First-Line ...
2.png
LBA8 Nivolumab (NIVO) + chemotherapy (chemo) vs chemo in patients (pts ...
Lung Cancer CCO Independent Conference Highlights of the 2015 ASCO ...
First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes ...
ESMO 2022: Tumor and Immune Features Associated with Disease-Free ...
Five-year outcomes with first-line nivolumab plus ipilimumab with 2 ...
First-line nivolumab plus ipilimumab combined with two cycles of ...
Partitioned survival model simulating the results of the CheckMate-648 ...
Comparative effectiveness of nivolumab versus clinical practice for ...
Immuno-oncology for Hepatocellular Carcinoma - Clinics in Liver Disease
checkmate,读音,意思(第2页)_大山谷图库
Administration of nivolumab plus ipilimumab: Infusion of the fixed ...
医药魔方
Indirect comparison of nivolumab ± ipilimumab (CheckMate 032) versus ...
Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus ...
Nivolumab in Patients With Advanced or Metastatic Malignancies ...
CheckMate-722: No Survival Benefit With Nivolumab Plus Chemotherapy in ...
Nivolumab Plus Brentuximab Vedotin Achieves High Event-Free Survival ...
Overall Survival in Patients With Advanced Melanoma Who Received ...
Neoadjuvant nivolumab + palbociclib + anastrozole for oestrogen ...
A multicenter, open-label, phase I study of nivolumab alone or in ...
PL02.08 Perioperative vs Neoadjuvant Nivolumab for Resectable NSCLC ...
ASH 2016 | Nivolumab monotherapy in R/R cHL: 12-month follow up of ...
First-line nivolumab plus ipilimumab in unresectable malignant pleural ...
Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage ...
CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab ...
Safety and Efficacy of Nivolumab in Patients With Advanced ...
Sequential administration of nivolumab and ipilimumab with a planned ...
Immunotherapy-based regimens for patients with EGFR-mutated non-small ...
Nivolumab versus chemotherapy in patients with advanced melanoma who ...
Survival study of neoadjuvant versus adjuvant chemotherapy with ...
Safety and efficacy of nivolumab plus ipilimumab in patients with ...
Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell ...
Safety of First-Line Nivolumab Plus Ipilimumab in Patients With ...
ESMO Virtual Congress 2020: A Phase 3, Randomized, Double-Blind Trial ...
Four-year clinical update and treatment switching-adjusted outcomes ...
・第III相CheckMate 722試験・・・EGFR-TKI耐性化後のニボルマブ+プラチナ併用化学療法 - 大分で肺癌診療
Efficacy of Nivolumab for Head and Neck Cancer Patients with Primary ...
(PDF) CheckMate-032 Study: Efficacy and Safety of Nivolumab and ...
Adjuvant nivolumab in muscle-invasive urothelial carcinoma: exploratory ...
Patient-reported outcomes of patients with advanced renal cell ...
Progress of the NSCLC Revolution (Transcript)
Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After ...
Nivolumab monotherapy in recurrent metastatic urothelial carcinoma ...
How to Integrate Perioperative Immunotherapy Into Multimodal Treatment ...
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of ...
Nivolumab in metastatic urothelial carcinoma after platinum therapy ...
CheckMate227研究6年随访结果公布,O+Y双免一线治疗持续改善mNSCLC患者生存 - 知乎